SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response	: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Jakobovits Aya		J Person [*]	2. Issuer Name and Ticker or Trading Symbol Adicet Bio, Inc. [ACET]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
				X Director 10% Owner				
				Officer (give title Other (specify				
(Last)	(First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022	below) below)				
C/O ADICE	T BIO, INC.		01/03/2022					
200 CLARENDON STREET, FLOOR 6		E FLOOR 6						
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)				X Form filed by One Reporting Person				
BOSTON	MA	02116		Form filed by More than One Reporting Person				
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed O	s Acquire f (D) (Ins	ed (A) or tr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	01/03/2022		S ⁽¹⁾		6,000	D	\$18.0208(2)	366,343	Ι	See Footnote ⁽³⁾
Common Stock	01/03/2022		S ⁽¹⁾		6,000	D	\$18.0218 ⁽⁴⁾	366,345	I	See Footnote ⁽⁵⁾
Common Stock	01/05/2022		S ⁽¹⁾		2,000	D	\$16.932(6)	364,343	I	See Footnote ⁽³⁾
Common Stock	01/05/2022		S ⁽¹⁾		2,000	D	\$16.8995(7)	364,345	Ι	See Footnote ⁽⁵⁾
Common Stock	02/09/2022		S ⁽¹⁾		4,000	D	\$14.0294 ⁽⁸⁾	360,343	Ι	See Footnote ⁽³⁾
Common Stock	02/09/2022		S ⁽¹⁾		4,000	D	\$14.0303 ⁽⁹⁾	360,345	Ι	See Footnote ⁽⁵⁾
Common Stock								138,076	I	See Footnote ⁽¹⁰⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispo of (D (Insti	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ate	Amount of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A) (D)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$18.00 to \$18.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$18.00 to \$18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

5. Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$16.41 to \$17.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$16.41 to \$17.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$14.00 to \$14.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$14.00 to \$14.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

10. Shares held in a revocable trust of which Dr. Jakobovits and her spouse are co-trustees.

Remarks:

/s/ Nick Harvey, Attorney-in- 02/14/2022

Fact for Aya Jakobovits

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.